NCT05690399

Brief Summary

To evaluate clinical and pathological characteristics and treatment protocol and outcomes of patients with prostate cancer in 2 centers of Asyut from 2013 to 2023

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2023

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

January 10, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 19, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
Last Updated

January 19, 2023

Status Verified

January 1, 2023

Enrollment Period

1.2 years

First QC Date

January 10, 2023

Last Update Submit

January 10, 2023

Conditions

Prostate Cancer

Outcome Measures

Primary Outcomes (1)

  • Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years

    Clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut in previous 10 years

    Baseline

Interventions

RadiotherapyRADIATION

Effect of radiotherapy on patients

Eligibility Criteria

Age40 Years+
Sexmale(Gender-based eligibility)
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy \- Newly diagnosed/ metastatic at presentation

You may qualify if:

  • Male patient , Age ≥ 40 yo
  • Diagnosed as prostate cancer from ( 2013- 2023 ) proved by biopsy
  • Newly diagnosed/ metastatic at presentation
  • ECOG 0-4

You may not qualify if:

  • Having Other types of malignancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Radiotherapy

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

  • Assiut University

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Aml Haridy

CONTACT

01061119919Amlmohamed1195@gmail.com

Heba Bakry

CONTACT

01007272760heba_bakri@aun.edu.eg

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Evaluation of clinical and pathological characteristics and routine treatment of patients with prostate cancer in 2 centers in Asyut

Study Record Dates

First Submitted

January 10, 2023

First Posted

January 19, 2023

Study Start

January 1, 2023

Primary Completion

March 1, 2024

Study Completion

April 1, 2024

Last Updated

January 19, 2023

Record last verified: 2023-01